Clinical trial

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

NCT05805631

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexedView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-08-01

PhasePHASE2

Conditions

Carcinoma, Non-Small-Cell Lungcandidate · MONDO: non-small cell lung carcinoma

Epidermal Growth Factor Receptorunresolved

Leptomeningeal Metastasisverified · MONDO: neoplastic meningitis

Interventions

PemetrexedDRUG · verified · RxNorm: pemetrexed

Sponsors & collaborators

Taipei Veterans General Hospital, Taiwanlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05805631 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.